Botox approved as overactive bladder treatment

Botox (botulinum toxin type A) can now be used to treat overactive bladder in patients inadequately managed by anticholinergics.

Botox is the only brand of botulinum toxin that is licensed for the treatment of overactive bladder
Botox is the only brand of botulinum toxin that is licensed for the treatment of overactive bladder

Already indicated for urinary incontinence due to neurogenic detrusor overactivity in patients with subcervical spinal cord injury or multiple sclerosis, Botox is now also licensed as a treatment for symptoms of urinary frequency, urgency and incontinence caused by overactive bladder. 

Fewer incontinence episodes

Two double-blind, placebo-controlled, 24-week phase III clinical studies examined the effect of Botox in this setting. Investigators randomised a total of 1,105 patients (mean age 60 years), whose symptoms had not been adequately managed with one or more anticholinergics, to receive either 100 Units of Botox (n=557) or placebo (n=548) by injection into the bladder wall. Participants were required to discontinue any anticholinergics before undergoing study treatment.

After 12 weeks, the mean number of  daily urinary incontinence episodes (co-primary endpoint) had decreased by 2.74 in patients who underwent Botox treatment and by 0.95 in those who received placebo (p<0.001). Overall, 61.8% of patients in the Botox group reported a positive response on the treatment benefit scale (second co-primary endpoint), compared with 28.0% of those in the placebo group (p<0.001). 

Botox is recommended by NICE as an option to treat overactive bladder caused by detrusor overactivity that has not responded to conservative management.

View Botox drug record

Further information: Allergan

Follow MIMS on Twitter  

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...

An older man in a blue shirt and beige trousers leans forward on a sofa rubbing his painful lower back. Promoted

Established muscle relaxant offers new approach to managing back pain

Sponsored by Mibe Pharma

A muscle relaxant that has been used for decades outside the UK may provide an alternative to current treatments for low back pain, explains Dr Sunny Nayee, consultant in anaesthesia and pain medicine at Imperial College NHS Healthcare Trust.

Sponsored by Mibe Pharma UK Ltd. UK/MYO/21/044; December 2021.

Click here to view prescribing information for Myopridin® (pridinol mesilate)